Cisplatin in combination with other drugs

GOG-110, GOG-0179, GOG-0169 (NCT00803062)

GOG-110, GOG-0179, GOG-0169 (NCT00803062)

GOG-110: The ifosfamide + cisplatin combination was superior to cisplatin alone in the secondary end point of response rates, but at the cost of increased toxicity.

GOG-110, GOG-0179, GOG-0169 (NCT00803062)

GOG-0179: The cisplatin + topotecan (CT) doublet combination had a significant advantage in OS compared with cisplatin alone, leading to approval of this indication for topotecan by the FDA. However, cisplatin alone underperformed in this trial because as many as 40% of the patients had already received cisplatin up front as a radiosensitizer.[18]

GOG-110, GOG-0179, GOG-0169 (NCT00803062)

GOG-0169: The paclitaxel + cisplatin (PC) combination, similarly, was superior in response rates and PFS, and its toxicity was similar to that of the single agent except in patients with GOG performance status 2 (scale: 0, asymptomatic–4, totally bedridden). Therefore, PC was chosen as the reference arm in GOG-0204 (NCT00064077).

GOG-0204 enrolled 513 patients and compared four cisplatin-based doublet regimens. The trial was closed early because no one experimental arm was likely to significantly lower the HRdeath relative to PC:[23]

GOG-0204 enrolled 513 patients and compared four cisplatin-based doublet regimens. The trial was closed early because no one experimental arm was likely to significantly lower the HRdeath relative to PC:[23]

1.15 (95% CI, 0.79–1.67) for vinorelbine + cisplatin (VC).

GOG-0204 enrolled 513 patients and compared four cisplatin-based doublet regimens. The trial was closed early because no one experimental arm was likely to significantly lower the HRdeath relative to PC:[23]

1.32 (95% CI, 0.91–1.92) for gemcitabine plus cisplatin.

GOG-0204 enrolled 513 patients and compared four cisplatin-based doublet regimens. The trial was closed early because no one experimental arm was likely to significantly lower the HRdeath relative to PC:[23]

1.27 (95% CI, 0.90–1.78) for CT. Trends in response rate, PFS, and OS favored CT.

GOG-0204 enrolled 513 patients and compared four cisplatin-based doublet regimens. The trial was closed early because no one experimental arm was likely to significantly lower the HRdeath relative to PC:[23]

Patients in the four study arms experienced different grades of neutropenia, infection, and alopecia.[23] There were no differences in health-related quality of life during treatment.[24] However, patients who received PC had more neurological side effects.